Immune control of HIV-1 after early treatment of acute infection - PubMed (original) (raw)
Clinical Trial
. 2000 Sep 28;407(6803):523-6.
doi: 10.1038/35035103.
Affiliations
- PMID: 11029005
- DOI: 10.1038/35035103
Clinical Trial
Immune control of HIV-1 after early treatment of acute infection
E S Rosenberg et al. Nature. 2000.
Abstract
Virus-specific T-helper cells are considered critical for the control of chronic viral infections. Successful treatment of acute HIV-1 infection leads to augmentation of these responses, but whether this enhances immune control has not been determined. We administered one or two supervised treatment interruptions to eight subjects with treated acute infection, with the plan to restart therapy if viral load exceeded 5,000 copies of HIV-1 RNA per millilitre of plasma (the level at which therapy has been typically recommended) for three consecutive weeks, or 50,000 RNA copies per ml at one time. Here we show that, despite rebound in viraemia, all subjects were able to achieve at least a transient steady state off therapy with viral load below 5,000 RNA copies per ml. At present, five out of eight subjects remain off therapy with viral loads of less than 500 RNA copies per ml plasma after a median 6.5 months (range 5-8.7 months). We observed increased virus-specific cytotoxic T lymphocytes and maintained T-helper-cell responses in all. Our data indicate that functional immune responses can be augmented in a chronic viral infection, and provide rationale for immunotherapy in HIV-1 infection.
Similar articles
- HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM. Steingrover R, et al. AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77. AIDS. 2008. PMID: 18670217 - Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE. Oxenius A, et al. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. doi: 10.1073/pnas.202372199. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370434 Free PMC article. Clinical Trial. - A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study. Fagard C, et al. Arch Intern Med. 2003 May 26;163(10):1220-6. doi: 10.1001/archinte.163.10.1220. Arch Intern Med. 2003. PMID: 12767960 - Immunologic control of HIV-1.
Gandhi RT, Walker BD. Gandhi RT, et al. Annu Rev Med. 2002;53:149-72. doi: 10.1146/annurev.med.53.082901.104011. Annu Rev Med. 2002. PMID: 11818468 Review. - HIV type 1-specific helper T cells: a critical host defense.
Rosenberg ES, Walker BD. Rosenberg ES, et al. AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S143-7. AIDS Res Hum Retroviruses. 1998. PMID: 9672231 Review. No abstract available.
Cited by
- Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection.
Reddy K, Lee GQ, Reddy N, Chikowore TJB, Baisley K, Dong KL, Walker BD, Yu XG, Lichterfeld M, Ndung'u T. Reddy K, et al. medRxiv [Preprint]. 2024 Oct 9:2024.02.16.24302713. doi: 10.1101/2024.02.16.24302713. medRxiv. 2024. PMID: 38947072 Free PMC article. Preprint. - Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control.
Jain A, Canepa GE, Liou ML, Fledderman EL, Chapoval AI, Xiao L, Mukherjee I, Balogun BM, Huaman-Vergara H, Galvin JA, Kumar PN, Bordon J, Conant MA, Boyle JS. Jain A, et al. Front Med (Lausanne). 2024 May 14;11:1342476. doi: 10.3389/fmed.2024.1342476. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38808136 Free PMC article. - Current situation in the development of a preventive HIV vaccine.
Alcamí J, Joseph Munné J, Muñoz-Fernández MÁ, Esteban M. Alcamí J, et al. Enferm Infecc Microbiol Clin. 2005 Jul;23:15-24. doi: 10.1016/S0213-005X(05)75157-0. Epub 2009 Jan 6. Enferm Infecc Microbiol Clin. 2005. PMID: 38620211 Free PMC article. - Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency.
Docken SS, McCormick K, Pampena MB, Samer S, Lindemuth E, Pinkevych M, Viox EG, Wu Y, Schlub TE, Cromer D, Keele BF, Paiardini M, Betts MR, Bar KJ, Davenport MP. Docken SS, et al. PLoS Pathog. 2023 Nov 30;19(11):e1011755. doi: 10.1371/journal.ppat.1011755. eCollection 2023 Nov. PLoS Pathog. 2023. PMID: 38032851 Free PMC article. - Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV.
Sponaugle A, Weideman AMK, Ranek J, Atassi G, Kuruc J, Adimora AA, Archin NM, Gay C, Kuritzkes DR, Margolis DM, Vincent BG, Stanley N, Hudgens MG, Eron JJ, Goonetilleke N. Sponaugle A, et al. Cell Rep Med. 2023 Nov 21;4(11):101268. doi: 10.1016/j.xcrm.2023.101268. Epub 2023 Nov 9. Cell Rep Med. 2023. PMID: 37949070 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical